What makes HEMLIBRA different from factor VIII?
HEMLIBRA offers QW (1.5 mg/kg), Q2W (3 mg/kg), and Q4W (6 mg/kg)
maintenance dosing after a QW loading dose (3 mg/kg) for 4 weeks.
more about dosing for HEMLIBRA.
QW=once weekly; Q2W=once every 2 weeks; Q4W=once every 4 weeks.
How may HEMLIBRA help target joints?
Where can I find information about managing pediatric patients with
Questions about breakthrough bleed management?
Patients without inhibitors taking HEMLIBRA can be treated with FVIII
in the event of a breakthrough bleed. 1 Remember, HEMLIBRA
cannot be used to treat a breakthrough bleed. To learn more about
breakthrough bleed management for patients with or without inhibitors,
Breakthrough Bleeds or download the Treating Breakthrough Bleeds Guide.
Questions about recreational activity level while on HEMLIBRA?
Specific guidelines on recreational activities should be based on the
patient's individual needs and goals. For information about
recreational activities, consider consulting the National Hemophilia
Foundation's guidelines, “Playing it Safe,” for safe activities for
people living with hemophilia A. You may want to consider reviewing
guidelines with your patients to determine which activities may be
safe for them to participate in. Genentech has no control over the
content of this site and is not responsible for the information
Questions about HEMLIBRA safety?
Looking for tools to help calculate your patient’s dose of HEMLIBRA?
Use the HEMLIBRA Dosing Calculator as a guide to help determine your patient's weight-based dose and vial size of HEMLIBRA. Infant dosing follows the same weight-based formula. 1 The information provided is not a substitute for clinical judgment.
To use the calculator, go to the Dosing Calculator page of this website.
There is no weight restriction or weight limitation for the use of
HEMLIBRA in the treatment of patients with hemophilia A.
Where can I find access and patient assistance resources?
Genentech Access Solutions will help walk your patients through their insurance coverage and financial assistance options for their Genentech medicines.
The HEMLIBRA Co-pay Program can help eligible patients with the OOP costs associated with HEMLIBRA.*
If patients don’t have insurance coverage or have financial concerns and meet eligibility criteria, they may be able to get free medicine from the Genentech Patient Foundation.†
Find out if your patients could be eligible by using the Patient Assistance Tool.
*This HEMLIBRA Co-pay Program is valid ONLY for patients with commercial insurance who have a valid prescription for a Food and Drug Administration (FDA)-approved indication of a Genentech medication. Patients using Medicare, Medicaid, or any other federal or state government program to pay for their medications are not eligible.
Under the Program, the patient will pay a co-pay. After reaching the maximum Program benefit, the patient will be responsible for all Out-of-Pocket costs.
All participants are responsible for reporting the receipt of all Program benefits as required by any insurer or by law. No party may seek reimbursement for all or any part of the benefit received through this Program. This Program is void where prohibited by law. Genentech reserves the right to rescind, revoke, or amend the Program without notice at any time. Additional eligibility criteria apply. See full terms and conditions at hemlibracopay.com.
†To be eligible for free Genentech medicine from the Genentech Patient Foundation, insured patients who have coverage for their medicine must have pursued all other forms of financial assistance and meet certain income requirements. Uninsured patients and insured patients without coverage for their medicine must meet different income requirements.